Clinical Trial Update: An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia [Phase 1, Phase 2]

View source ↗

Summary

An extension study of KRN23 (burosumab) in adults with X-linked hypophosphatemia has completed Phase 1/Phase 2, with results posted in February 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: X-linked Hypophosphatemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-17